Table 1.
MicroRNA | Mean | Median | SD | CV (%) | Rho | BRCA * | geNorm | NormFinder ** | ||
---|---|---|---|---|---|---|---|---|---|---|
CV (%) | M | All | Prim | Metas | ||||||
hsa-miR-222-3p | 26.97 | 26.77 | 2.13 | 7.88 | 0.86 | 21.6 | 1.14 | 0.95 | 0.63 | 1.29 |
hsa-miR-16-5p | 25.70 | 24.84 | 2.78 | 10.80 | 0.83 | 9.3 | 1.26 | 1.28 | 1.42 | 0.61 |
hsa-miR-126-3p | 25.17 | 24.70 | 2.08 | 8.26 | 0.80 | 9.6 | 1.03 | 0.62 | 0.50 | 0.86 |
hsa-miR-29a-3p | 27.46 | 27.23 | 2.12 | 7.73 | 0.80 | 6.0 | 1.06 | 0.86 | 0.80 | 1.02 |
hsa-miR-146a-5p | 27.82 | 27.54 | 2.00 | 7.18 | 0.76 | 20.3 | 1.03 | 0.75 | 0.67 | 0.93 |
hsa-miR-191-5p | 25.21 | 24.68 | 2.42 | 9.60 | 0.71 | 10.8 | 1.21 | 0.98 | 1.06 | 0.74 |
U6snRNA | 19.14 | 18.76 | 2.24 | 11.73 | 0.69 | – | 1.50 | 1.33 | 1.48 | 0.87 |
hsa-miR-199-3p | 28.68 | 28.50 | 2.33 | 8.13 | 0.68 | 8.9 | 1.42 | 1.35 | 1.31 | 1.48 |
hsa-miR-628-5p | 33.16 | 33.17 | 1.83 | 5.52 | 0.64 | 34.4 | 1.78 | 1.90 | 1.98 | 1.51 |
hsa-miR-145-5p | 27.59 | 27.18 | 2.47 | 8.95 | 0.60 | 10.4 | 1.36 | 1.44 | 1.48 | 1.35 |
hsa-miR-150-5p | 27.94 | 27.80 | 2.23 | 7.98 | 0.58 | 20.4 | 1.57 | 1.49 | 1.44 | 1.62 |
hsa-miR-196b-5p | 31.63 | 31.62 | 2.03 | 6.43 | 0.50 | 20.4 | 1.68 | 1.85 | 1.49 | 1.84 |
SD: standard deviation; CV: coefficient of variation; rho: Spearman rank correlation, microRNAs with a rho ≥ 0.8 are greyed out; M: average expression stability value; PRIM: primary tumor; METAS: Metastasis; ALL: all 58 patients; * microRNAseq data of the The Cancer Genome Atlas (TCGA) breast adenocarcinoma (BRCA) analysis (including 755 patients); ** Stability values from NormFinder analysis are given based on the estimated intragroup variance for the given group.